60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · Real-Time Price · USD
1.170
-0.080 (-6.40%)
At close: Jul 31, 2026, 4:00 PM EDT
1.180
+0.010 (0.85%)
Pre-market: Aug 3, 2026, 5:13 AM EDT
60 Degrees Pharmaceuticals Employees
60 Degrees Pharmaceuticals had 3 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$438,301
Profits / Employee
-$2,695,344
Market Cap
3.11M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3 | 0 | - |
| Dec 31, 2024 | 3 | 0 | - |
| Dec 31, 2023 | 3 | 1 | 50.00% |
| Dec 31, 2022 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| FibroBiologics | 15 |
| Genprex | 13 |
| Ensysce Biosciences | 10 |
| Revelation Biosciences | 9 |
| Artelo Biosciences | 7 |
| Ernexa Therapeutics | 7 |
| Jupiter Neurosciences | 5 |
SXTP News
- 3 days ago - 60 Degrees Pharmaceuticals to sell shares and warrants in private placement - TheFly
- 3 days ago - 60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 4 days ago - 60 Degrees Pharma babesiosis interim readout planned by October 6 - TheFly
- 4 days ago - 60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026 - GlobeNewsWire
- 25 days ago - 60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases - GlobeNewsWire
- 4 weeks ago - 60 Degrees Pharmaceuticals Proxy statement: Proxy filing - Filings
- 4 weeks ago - 60 Degrees Pharmaceuticals announces DSMB recommendation for B-Free study - TheFly
- 4 weeks ago - 60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue - GlobeNewsWire